GlassScriptPhysician profile
Christine D Brown
NPI 1063460715
$7,131.33
in general payments reported to CMS, 2019-2025
34 companies · $798 in 2025
The $798 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $706 · 2020: $663 · 2021: $753 · 2022: $1,228 · 2023: $1,520 · 2024: $1,464 · 2025: $798.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,690 · Education: $91.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,690.27 |
| Education | $91.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $1,186.39 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $856.27 | 2019-2025 | Absorica Ld, Winlevi, Ilumya |
| Lilly USA, LLC | $636.22 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Pfizer INC. | $500.74 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $437.65 | 2020-2025 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $379.97 | 2022-2025 | Sotyktu |
| Abbvie INC. | $378.40 | 2019-2024 | Rinvoq, Skyrizi |
| Genzyme Corporation | $370.45 | 2020-2025 | |
| Galderma Laboratories, L.P. | $327.23 | 2019-2025 | Aklief, Oracea, Twyneo |
| Organogenesis INC. | $310.44 | 2021-2025 | Puraply, Cygnus Dual |
| Leo Pharma INC. | $261.84 | 2019-2023 | Adbry |
| Amgen INC. | $234.62 | 2020-2024 | Otezla |
| Arcutis Biotherapeutics, INC. | $221.17 | 2023-2025 | Zoryve |
| Revance Therapeutics, INC. | $135.21 | 2024 | Daxxify |
| Ucb, INC. | $123.89 | 2024-2025 | Bimzelx |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $117.10 | 2019-2025 | Klisyri, Seysara |
| Biofrontera INC. | $116.04 | 2019-2021 | |
| Dusa Pharmaceuticals, INC. | $66.91 | 2019 | |
| Merz North America, INC. | $56.09 | 2022-2023 | |
| Encore Dermatology INC. | $55.20 | 2020 | |
| Botanix Sb INC | $52.11 | 2025 | Sofdra |
| Dermira, INC. | $35.15 | 2020-2021 | |
| Paratek Pharmaceuticals, INC. | $30.51 | 2025 | Nuzyra |
| Celgene Corporation | $29.59 | 2019 | |
| Janssen Biotech, INC. | $27.44 | 2025 | Tremfya |
| Sandoz INC. | $24.55 | 2021 | |
| Novartis Pharmaceuticals Corporation | $23.80 | 2022 | |
| Shield Therapeutics INC | $22.40 | 2025 | |
| Tempus Ai, INC | $21.11 | 2024 | Merlin Test |
| Glenmark Therapeutics INC. | $21.00 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $20.85 | 2021 | |
| Taro Pharmaceuticals USA, INC. | $20.31 | 2019 | |
| Incyte Corporation | $19.47 | 2022 | |
| Merck Sharp & Dohme LLC | $11.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christine Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.